Research Peptide
$79.99
Combined growth hormone secretagogue blend for GH axis research. Lyophilized powder, ≥99% purity verified via HPLC and mass spectrometry. Certificate of Analysis included with every order. For research and laboratory use only.
CJC-1295 (no DAC) and Ipamorelin are combined in this dual-compound formulation for studying synergistic growth hormone secretagogue activity. CJC-1295 acts as a GHRH analog while Ipamorelin acts as a selective ghrelin receptor agonist, enabling researchers to study complementary GH axis stimulation pathways simultaneously.
Each vial contains pharmaceutical-grade lyophilized CJC-1295 (5mg) and Ipamorelin (5mg) powder, sealed under sterile conditions for maximum stability and shelf life. Both compounds are independently verified to ≥99% purity by third-party HPLC and mass spectrometry analysis.
Available in a 5mg/5mg configuration for in-vitro research protocols.
| Compound | CJC-1295 (no DAC) + Ipamorelin |
| Purity | ≥99% (HPLC verified) |
| Form | Lyophilized powder |
| Size | 5mg / 5mg |
| Storage | Store at -20°C. Protect from light. |
| Reconstitution | Bacteriostatic water or sterile saline |
| Molecular Targets | GHRH receptor + GHS receptor |
| Testing | HPLC, Mass Spectrometry, Endotoxin |
| COA | Included with every order |
CJC-1295 and Ipamorelin have been extensively studied individually and in combination in preclinical research. Key areas of published in-vitro and animal model research include:
All research references are available upon request. This compound is sold exclusively for in-vitro and laboratory research use.
All sales are final once shipped. Refunds available only if order hasn't shipped or wrong product received — contact us within 7 days.
CJC + Ipamorelin
$79.99
All products are for research and laboratory use only. Not for human consumption.
